OPAL Fuels Secures New Capital for Growth and Expansion
Money

OPAL Fuels Secures New Capital for Growth and Expansion

authorBy Bola Sokunbi
DateMar 14, 2026
Read time2 min

OPAL Fuels Inc. (NASDAQ:OPAL) recently finalized a significant financial arrangement, securing a new preferred stock facility valued at $180 million. This capital infusion, provided by an affiliate of its main shareholder, Fortistar, marks a pivotal moment for the company's strategic growth. The initial drawdown from this facility amounted to $120 million, with an additional $60 million reserved for future needs, demonstrating a strong commitment to funding its expansion and operational objectives. This financing is expected to play a crucial role in advancing OPAL Fuels' position within the renewable energy sector.

A substantial portion of the initial funding, specifically around $100 million, has been strategically used to repurchase the Series A Preferred Units previously owned by Mendocino Capital, LLC, a wholly-owned subsidiary of NextEra Energy, Inc. This move not only streamlines OPAL Fuels' equity structure but also frees up capital for reinvestment into core business initiatives. The remaining funds are earmarked for broad corporate applications, including enhancing working capital, supporting capital expenditures, and facilitating project-specific financing. These financial maneuvers are poised to bolster the company's capacity for developing new renewable natural gas ventures and strengthening its fueling infrastructure, particularly for the heavy-duty transportation sector.

OPAL Fuels Inc. stands as a key player in the production and distribution of renewable natural gas, serving the heavy-duty trucking and broader transportation markets. The company's commitment extends to both developing and operating renewable natural gas production facilities and establishing comprehensive fueling infrastructure across the United States. This strategic financial backing from Fortistar, coupled with the methodical application of funds towards project development and corporate growth, positions OPAL Fuels for a dynamic expansion phase. The 12% annual preferred quarterly distributions on the new Series A Preferred Units underscore the long-term investment and growth potential recognized by its stakeholders.

The financial strengthening of OPAL Fuels is a testament to the increasing global demand for sustainable energy solutions. By focusing on renewable natural gas, the company not only contributes to environmental stewardship but also offers a viable alternative for heavy-duty transport, paving the way for a greener future. This forward-thinking approach, supported by strategic investments, reflects a positive outlook for the renewable energy industry and its capacity to drive innovation and create a more sustainable world for all.

More Articles
RIN Price Decline Impacts Montauk Renewables' 2025 Performance
Montauk Renewables experienced a downturn in its 2025 financial performance, largely due to a significant decrease in average realized Renewable Identification Number (RIN) prices. Despite increased natural gas index pricing and higher RIN volumes sold, the company's revenue remained stagnant, while net income and operating income saw substantial reductions. This financial strain was exacerbated by elevated operational and maintenance expenses across its renewable natural gas facilities. For 2026, Montauk projects growth in both renewable natural gas and renewable electricity revenues, driven by an anticipated new project.
By Bola SokunbiMar 14, 2026
Cogent Biosciences: A Promising Biotech Investment for Billionaires?
Cogent Biosciences (COGT) is gaining attention as a potential top investment among billionaires. The company reported strong 2025 earnings and is making significant regulatory progress with its lead drug, bezuclastinib, for mastocytosis and gastrointestinal stromal tumors. With a solid cash position extending into 2028, Cogent is also expanding its pipeline with new selective inhibitors, positioning itself for future growth and continued innovation in precision therapies.
By Natalie PaceMar 14, 2026
Stem's Stock Target Reduced by UBS Despite Revenue Mix Improvement
UBS revised down its price target for Stem Inc. to $12 from $18, maintaining a Neutral rating. This adjustment follows a revised outlook for software sales and lower adjusted EBITDA forecasts for 2026-2028. Despite a 15% revenue decrease in Q4 2025 due to reduced battery hardware sales, the company saw a 62% rise in software, services, and edge hardware revenue. Stem achieved an improved non-GAAP gross margin and a narrowed net loss, along with positive full-year adjusted EBITDA.
By Ramit SethiMar 14, 2026
Nvidia's Future: Analyst Insights Before GTC 2026
As Nvidia approaches its annual GTC conference in 2026, analysts are keenly observing several aspects that could influence the company's stock performance. This report delves into BofA's optimistic outlook and highlights three critical areas: the next-generation Feynman GPU, advancements in low-latency and inference technologies, and breakthroughs in networking and quantum computing. Additionally, the article examines Nvidia's current valuation, robust financial standing, and strong earnings performance, underscoring why many experts believe the stock is ripe for investment.
By Ramit SethiMar 14, 2026
SunPower's Convertible Debenture: A Deep Dive into Share Limitations
SunPower recently secured a $10 million convertible debenture from YA II PN, Ltd., priced at 90% of its principal. This financing, intended to bolster SunPower's operations in residential solar and energy solutions, comes with stringent share limitations and a structured repayment plan. The debenture features a 0% interest rate, escalating to 18% upon default, and mandates a registration statement filing by April 30, 2026, alongside an exchange cap of nearly 22.4 million shares.
By Scott PapeMar 14, 2026